November 28, 2006

PRESS RELEASE

Clifton Mining Company Inc. (OTC : CFTN)
FOR RELEASE – November 28, 2006

American Biotech Labs Receives New EPA Approvals

ALPINE, UT – November 28, 2006 – Clifton Mining Company Inc. (OTC: CFTN) today announced that American Biotech Labs (ABL), a private company in which Clifton Mining owns a 23 percent interest, has just received its fourth set of EPA approvals. These approvals govern the use of ASAP-AGX-32® against additional pathogens. They broaden the range of bacteria for which this product is approved to and include yeasts and environmental fungi.
 
The Nature of the Tests
These most recent tests were exceptionally stringent. They involved using the ASAP-AGX-32® against high concentrations of a variety of pathogens to kill all colony forming units within 10 minutes. All tests were successful.
 
Black Mold
One of the most important new approvals was for environmental fungi, including black mold.  Black mold is common in buildings throughout the U.S., and often causes upper respiratory tract infections. Black mold is notoriously difficult to kill, and to the best of ABL leadership’s knowledge, ABL’s ASAP-AGX-32® is the only non-toxic and non-irritating product that has received EPA approval for this use.
 
“We believe our nano-silver product is an important non-toxic broad-spectrum anti-pathogenic,” said Keith Moeller, VP of marketing for ABL. “It is gratifying to receive additional approvals that extend the range of accepted use for this product, as we continue to work to further extend the range of applications for this technology, which is now backed by patent #7135195.” 

Clifton trades on the U.S. OTC: (CFTN). For additional information, contact Dr. Ken Friedman, president of Clifton Mining (303-642-0659); Keith Moeller, VP of marketing for ABL (801-756-1414); or visit Clifton Mining’s website at www.cliftonmining.com or American Biotech Labs at www.americanbiotechlabs.com.

###

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company’s business prospects and performance.